Ocugen (OCGN) Capital Leases (2018 - 2019)
Ocugen's (OCGN) quarterly Capital Leases came in at $17339.0 in Q3 2019, down 48.58% on a QoQ basis from $33720.0 in Q4 2018.
Powered by 
Analysis
Ocugen (OCGN) Capital Leases (2018 - 2019) Analysis & Trends
Ocugen (OCGN) has 2 years of Capital Leases data on file, last reported at $17339.0 in Q3 2019.
- Quarterly Capital Leases changed N/A year-over-year to $17339.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $17339.0 (changed N/A YoY) and the FY2018 annual result came in at $33720.0, changed N/A from the prior year.
- Capital Leases fell to $17339.0 in Q3 2019, from $33720.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $33720.0 in Q4 2018 to a low of $17339.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - |